Factor VII-activating protease (FSAP): Vascular functions and role in atherosclerosis

Summary

FSAP is a plasma serine protease for which a potential role in the regulation of coagulation and fibrinolysis is postulated, based on its property to activate factorVII (FVII) as well as pro-urokinase (uPA). In clinical studies, the G534E single nucleotide polymorphism (Marburg I) of FSAP has been linked to late complications of atherothrombosis and is associated with a low proteolytic activity, particularly, towards pro-uPA. This has stimulated much interest in a search for additional functions of FSAP in the cardiovascular system. FSAP is a potent inhibitor of vascular smooth muscle cell proliferation and migration in vitro and local application of FSAP (but not Marburg I variant) in animal models reduces neointima formation. This is due to a reduced proteolytic activity of the variant isoform towards platelet derived growth factor-BB, a key mediator of neointima development. Moreover, appreciable quantities of FSAP are localized to unstable atherosclerotic plaques and may contribute to plaque instability. These data indicate that the cellular regulatory effects of FSAP may be more important than its influence on haemostasis. In this review the contribution of FSAP to vascular fibroproliferative inflammatory diseases in the context of pericellular proteolysis of the extracellular matrix, growth factor activity and haemostasis will be highlighted.

Keywords

Atherosclerosis - restenosis - blood coagulation - fibrinolysis - serine protease - growth factors - cell proliferation

• References

• 1 Choi-Miura NH, Tobe T, Sumiya J. et al. Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator. J Biochem (Tokyo) 1996; 119: 1157-1165.
• 2 Hashimoto K, Tobe T, Sumiya J. et al. Cloning of the cDNA for a mouse homologue of human PHBP: a novel hyaluronan-binding protein. Biol Pharm Bull 1997; 20: 1127-1130.
• 3 Kannemeier C, Feussner A, Stohr HA. et al. Factor VII and single-chain plasminogen activator-activating protease: activation and autoactivation of the proenzyme. Eur J Biochem / FEBS 2001; 268: 3789-3796.
• 4 Etscheid M, Hunfeld A, Konig H. et al. Activation of proPHBSP, the zymogen of a plasma hyaluronan binding serine protease, by an intermolecular autocatalytic mechanism. Biol Chem 2000; 381: 1223-1231.
• 5 Nakazawa F, Kannemeier C, Shibamiya A. et al. Extracellular RNA is a natural cofactor for the (auto-)activation of factor VII-activating protease (FSAP). Biochem J 2005; 385: 831-838.
• 6 Altincicek B, Shibamiya A, Trusheim H. et al. A positively charged cluster in the epidermal growth factor-like domain of Factor VII-activating protease (FSAP) is essential for polyanion binding. Biochem J 2006; 394: 687-692.
• 7 Hunfeld A, Etscheid M, Konig H. et al. Detection of a novel plasma serine protease during purification of vitamin K-dependent coagulation factors. FEBS Lett 1999; 456: 290-294.
• 8 Choi-Miura NH, Takahashi K, Yoda M. et al. Proteolytic activation and inactivation of the serine protease activity of plasma hyaluronan binding protein. Biol Pharm Bull 2001; 24: 448-452.
• 9 Etscheid M, Beer N, Seitz R. et al. Regulation of the plasma hyaluronan binding serine protease. Ann Haematol 2002; 81: A16.
• 10 Choi-Miura NH, Saito K, Takahashi K. et al. Regulation mechanism of the serine protease activity of plasma hyaluronan binding protein. Biol Pharm Bull 200 24: 221-225.
• 11 Romisch J, Vermohlen S, Feussner A. et al. The FVII activating protease cleaves single-chain plasminogen activators. Haemostasis 1999; 29: 292-299.
• 12 Wygrecka M, Morty RE, Markart P. et al. Plasminogen activator inhibitor-1 is an inhibitor of factor VII-activating protease in patients with acute respiratory distress syndrome. J Biol Chem 2007; 282: 21671-21682.
• 13 Muhl L, Nykjaer A, Wygrecka M. et al. Inhibition of PDGF-BB by Factor VII-activating protease (FSAP) is neutralized by protease nexin-1, and the FSAP-inhibitor complexes are internalized via LRP. Biochem J 2007; 404: 191-196.
• 14 Romisch J. Factor VII activating protease (FSAP): a novel protease in hemostasis. Biol Chem 2002; 383: 1119-1124.
• 15 Romisch J, Feussner A, Vermohlen S. et al. A protease isolated from human plasma activating factor VII independent of tissue factor. Blood Coagul Fibrinol 1999; 10: 471-479.
• 16 Choi-Miura NH, Yoda M, Saito K. et al. Identification of the substrates for plasma hyaluronan binding protein. Biol Pharm Bull 2001; 24: 140-143.
• 17 Etscheid M, Beer N, Fink E. et al. Kinin release from HMW kininogen by the plasma hyaluronan binding protease. Ann Haematol 2002; 81: A16.
• 18 Colman RW. Biologic activities of the contact factors in vivo–potentiation of hypotension, inflammation, and fibrinolysis, and inhibition of cell adhesion, angiogenesis and thrombosis. Thromb Haemost 1999; 82: 1568-1577.
• 19 Roemisch J, Feussner A, Nerlich C. et al. The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP). Blood Coagul Fibrinol 2002; 13: 433-441.
• 20 Willeit J, Kiechl S, Weimer T. et al. Marburg I polymorphism of factor VII--activating protease: a prominent risk predictor of carotid stenosis. Circulation 2003; 107: 667-670.
• 21 Ireland H, Miller GJ, Webb KE. et al. The factor VII activating protease G511E (Marburg) variant and cardiovascular risk. Thromb Haemost 2004; 92: 986-992.
• 22 Hoppe B, Tolou F, Radtke H. et al. Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. Blood 2005; 105: 1549-1551.
• 23 Hoppe B, Tolou F, Dorner T. et al. Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: frequency distribution in a healthy German population. Thromb Haemost 2006; 96: 465-470.
• 24 Gulesserian T, Hron G, Endler G. et al. Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism. Thromb Haemost 2006; 95: 65-67.
• 25 Sedding D, Daniel JM, Muhl L. et al. The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation. J Exp Med 2006; 25 203: 2801-2807.
• 26 Tag CG, Mengsteab S, Kanse SM. et al. Rapid genotyping of the G534E polymorphism (Marburg I) of the gene encoding the factor VII-activating protease (FSAP) by LightCycler PCR. Clin Biochem 2007; 40: 1063-1064.
• 27 Parahuleva MS, Kanse SM, Parviz B. et al. Factor Seven Activating Protease (FSAP) expression in human monocytes and accumulation in unstable coronary atherosclerotic plaques. Atherosclerosis. 2007 in press.
• 28 Kannemeier C, Al-Fakhri N, Preissner KT. et al. Factor VII-activating protease (FSAP) inhibits growth factor-mediated cell proliferation and migration of vascular smooth muscle cells. FASEB J 2004; 18: 728-730.
• 29 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
• 30 Shibamiya A, Muhl L, Tannert-Otto S. et al. Nucleic acids potentiate Factor VII-activating protease (FSAP)-mediated cleavage of platelet-derived growth factor-BB and inhibition of vascular smooth muscle cell proliferation. Biochem J 2007; 404: 45-50.
• 31 Etscheid M, Beer N, Kress JA. et al. Inhibition of bFGF/EGF-dependent endothelial cell proliferation by the hyaluronan-binding protease from human plasma. Eur J Cell Biol 2004; 82: 597-604.
• 32 Jeon JW, Song HS, Moon EJ. et al. Anti-angiogenic action of plasma hyaluronan binding protein in human umbilical vein endothelial cells. Int J Oncol 200 29: 209-215.
• 33 Kress JA, Seitz R, Dodt J. et al. Induction of intracellular signalling in human endothelial cells by the hyaluronan-binding protease involves two distinct pathways. Biol Chem 2006; 387: 1275-1283.
• 34 Wygrecka M, Markart P, Fink L, Guenther A, Preissner KT. Raised protein levels and altered cellular expression of factor VII activating protease (FSAP) in the lungs of patients with acute respiratory distress syndrome (ARDS). Thorax 2007; 62: 880-888.